BLOCKING DRUGS


•  Clinical Considerations


•  Indications: Bolus dosing used for rapid sequence induction when aspiration is a risk (i.e., full stomach, trauma, diabetes mellitus, hiatal hernia, obesity, pregnancy); infusion useful in very short surgical procedures requiring relaxation


•  Precautions


• Known MH trigger—contraindicated in susceptible patients


• Can ↑ intraocular and intracranial pressure (caution in eye and head injuries), however intubation without adequate relaxation will also ↑ IOP/ICP


• Avoid conditions with extrajunctional ACh receptor proliferation due to potential for ↑↑ potassium release, hyperkalemia (burn pts → probably safe if given <24 hrs or >6 mos of injury; spinal cord transection pts → probably safe if given <24 hrs of injury)


• Limit use in young male patients due to potential for undiagnosed muscular dystrophy and hyperkalemic arrest


•  Adverse Effects


• Cardiac: Sinus bradycardia, junctional rhythm, asystole due to stimulation of cardiac muscarinic receptors (especially in patients with ↑ vagal tone, e.g., children). More likely to occur when a second dose of SCh is given within minutes. Pretreatment with atropine may prevent such responses. May also cause tachycardia via ↑ catecholamine release


• Hyperkalemia: Serum K+ transiently ↑ by 0.5–1.0 mEq/L, may be significant in patients with underlying hyperkalemia. As above, ↑↑ K+ release may occur in patients with burns, trauma (especially crush), acidosis, severe infections, prolonged immobility, denervation, stroke, myotonia, muscular dystrophy, and spinal cord injuries


• Allergic reactions: NMBDs are responsible for >50% of the anaphylactic reactions occurring during anesthesia. SCh is the most common cause, followed by rocuronium


• Myalgias: Fasciculation caused by SCh may contribute to postoperative myalgias. Pretreatment with a low dose of a non-depolarizing NMBD (i.e., 1 mg of vecuronium) may decrease the incidence


• Masseter spasm: Sustained contraction of masseter muscle may complicate intubation; can be an early sign of MH though not consistently related (see Appendix C for malignant hyperthermia)


• Increased intragastric pressure: Lower esophageal sphincter tone also ↑, thus no apparent ↑ aspiration risk



ANTAGONISM OF NON-DEPOLARIZING NEUROMUSCULAR BLOCKADE


Cholinesterase Inhibitors


•  Inhibit acetylcholinesterase, thereby allowing ACh to build up at the NMJ and overcome competitive inhibition non-depolarizers


•  Consider relative duration of action of NMBD and reversal agent; administration of reversal after some degree of spontaneous recovery helps prevent “recurarization” (increased weakness in PACU due to lasting effect of NMBD). Note that 70% of ACh receptors may still be blocked with apparently normal TOF



•  Common cholinergic side effects of anticholinesterases:


• Cardiac muscarinic effects (bradycardia, sinus arrest). Minimized by concurrent dosing of an anticholinergic drug of similar onset time (glycopyrrolate with neostigmine, atropine with edrophonium; see Chapter 2H-59 for more information on anticholinergics)


• Bronchospasm, ↑ secretions, miosis, nausea, ↑ peristalsis


• Nicotinic effects, especially paradoxical muscle weakness with large doses


• Neostigmine may cross placenta and cause fetal bradycardia, consider concurrent administration of atropine (glycopyrrolate does not cross placenta)


Physostigmine


•  Limited usefulness as reversal agent due to penetration of blood–brain barrier; may cause central cholinergic effects (delirium, seizures, impaired consciousness, respiratory depression)


•  Used to treat central anticholinergic syndrome (see page 2H-66)




Sugammadex (Proposed Trade Name: Bridion)


•  Selective relaxant binding agent—cyclodextrin molecule encapsulates steroid NMBD, rendering it incapable of binding at the NMJ (not currently FDA approved due to hypersensitivity concerns)


•  Strongest affinity for rocuronium, may have role in vecuronium and pancuronium reversal as well


•  Advantages:


• Can be given at any time after administration of rocuronium, thereby resulting in fast recovery of profound neuromuscular blockade


• Mechanism does not rely on AChE inhibition, therefore no undesirable cardiac effects


Only gold members can continue reading. Log In or Register to continue

Stay updated, free articles. Join our Telegram channel

Aug 28, 2016 | Posted by in ANESTHESIA | Comments Off on BLOCKING DRUGS

Full access? Get Clinical Tree

Get Clinical Tree app for offline access